Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Sexually Transmitted Diseases

Free Subscription Articles published in Oral Oncol Retrieve available abstracts of 72 articles: HTML format

Single Articles

March 2023
1. LAMBERT T, Tasoulas J, Flores M, Sheth S, et al
   Circulating tumor HPV DNA as an alternative method to determine HPV status in oropharyngeal squamous cell carcinoma.
   Oral Oncol. 2023;140:106361.
   PubMed     Abstract available
   
   
   
2. ZHANG L, Freeman T, Sun S, Bhateja P, et al
   The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.
   Oral Oncol. 2023;139:106357.
   PubMed    
   
   
   
3. DE SOUSA LG, Lazar Neto F, Dal Lago EA, Sikora A, et al
   Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma.
   Oral Oncol. 2023;138:106311.
   PubMed     Abstract available
   
   
   February 2023
4. BALLAL Y, Gete M, Su J, O'Sullivan B, et al
   The collateral impact of the COVID-19 pandemic on HPV-positive oropharyngeal cancer diagnosis.
   Oral Oncol. 2023;138:106332.
   PubMed     Abstract available
   
   
   
5. BOOT PA, Mes SW, de Bloeme CM, Martens RM, et al
   Magnetic resonance imaging based radiomics prediction of Human Papillomavirus infection status and overall survival in oropharyngeal squamous cell carcinoma.
   Oral Oncol. 2023;137:106307.
   PubMed     Abstract available
   
   
   January 2023
6. HALLER TJ, Yin XL, O'Byrne TJ, Moore EJ, et al
   30-day morbidity and mortality after transoral robotic surgery for human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma: A retrospective analysis of two prospective adjuvant de-escalation trials (MC1273 & MC1675).
   Oral Oncol. 2023;137:106248.
   PubMed     Abstract available
   
   
   December 2022
7. IDA S, Takahashi H, Tada H, Mito I, et al
   Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
   Oral Oncol. 2022;137:106296.
   PubMed     Abstract available
   
   
   
8. PERES MA, Huihua L, Antunes JLF, Perea LME, et al
   Time trend and Age-Period-Cohort analysis of potentially HPV-related oral and pharyngeal cancer incidence in Singapore between 1968 and 2017.
   Oral Oncol. 2022;136:106272.
   PubMed     Abstract available
   
   
   
9. TAPIA M, Manji J, Dhillon K, Kleid S, et al
   The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection.
   Oral Oncol. 2022;135:106213.
   PubMed     Abstract available
   
   
   November 2022
10. GHEIT T, Muwonge R, Lucas E, Galati L, et al
    Impact of HPV vaccination on HPV-related oral infections.
    Oral Oncol. 2022;136:106244.
    PubMed     Abstract available
    
    
    
11. CHAN JYK, Cheung MK, Lan L, Ng C, et al
    Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes.
    Oral Oncol. 2022;135:106245.
    PubMed     Abstract available
    
    
    October 2022
12. MORSE RT, Beaty B, Scanga L, Blumberg J, et al
    Corrigendum to "Diagnostic accuracy of FNA to determine HPV status in HPV-associated oropharyngeal squamous cell carcinoma" [Oral Oncol. 134 (2022) 106131].
    Oral Oncol. 2022 Oct 20:106212. doi: 10.1016/j.oraloncology.2022.106212.
    PubMed    
    
    
    
13. MANJUSHA M, Yasasve M, Manojj D, Saravanan M, et al
    Role of human papilloma virus in the cross-talk mechanism between NF-kappaB and specific AP-1 proteins during tongue carcinogenesis.
    Oral Oncol. 2022;133:106062.
    PubMed    
    
    
    September 2022
14. MORSE RT, Beaty B, Scanga L, Blumberg J, et al
    Diagnostic accuracy of FNA to determine HPV status in HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;134:106131.
    PubMed     Abstract available
    
    
    August 2022
15. DONA MG, Rollo F, Pichi B, Moretto S, et al
    Updates on Human Papillomavirus-driven oropharyngeal squamous cell carcinomas in a southern European country.
    Oral Oncol. 2022;131:105947.
    PubMed    
    
    
    June 2022
16. YANG Z, Liao J, Schumaker L, Carter-Cooper B, et al
    Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Oral Oncol. 2022;131:105939.
    PubMed     Abstract available
    
    
    May 2022
17. SHIAO JC, Holt D, Ladbury C, Gao D, et al
    The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;130:105907.
    PubMed     Abstract available
    
    
    
18. LOW SK, Reed CT, Millo C, Turkbey EB, et al
    Cecal mass: An unusual site of metastasis from HPV-associated oropharyngeal cancer.
    Oral Oncol. 2022;130:105928.
    PubMed    
    
    
    
19. BURMAN B, Drutman SB, Fury MG, Wong RJ, et al
    Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies.
    Oral Oncol. 2022;128:105806.
    PubMed     Abstract available
    
    
    April 2022
20. SARODE SC, Sarode GS, Sengupta N
    Strengthening koilocyte as a biomarker of HPV infection: A need of the hour.
    Oral Oncol. 2022;129:105891.
    PubMed    
    
    
    
21. LIU T, Ma L, Song L, Yan B, et al
    CENPM upregulation by E5 oncoprotein of human papillomavirus promotes radiosensitivity in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;129:105858.
    PubMed     Abstract available
    
    
    
22. ZHOU S, Chan C, Rulach R, Dyab H, et al
    Long term survival in patients with human papillomavirus-positive oropharyngeal cancer and equivocal response on 12-week PET-CT is not compromised by the omission of neck dissection.
    Oral Oncol. 2022;128:105870.
    PubMed     Abstract available
    
    
    March 2022
23. MATTOX AK, D'Souza G, Khan Z, Allen H, et al
    Comparison of next generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2022;128:105805.
    PubMed     Abstract available
    
    
    
24. BRODY RM, Shimunov D, Cohen RB, Lin A, et al
    A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers.
    Oral Oncol. 2022;127:105798.
    PubMed     Abstract available
    
    
    February 2022
25. QURESHI HA, Zhu X, Yang GH, Steadele M, et al
    Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;127:105774.
    PubMed     Abstract available
    
    
    
26. HARING CT, Dermody SM, Yalamanchi P, Kang SY, et al
    The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2022;126:105776.
    PubMed     Abstract available
    
    
    
27. CHIN O, Alshafai L, O'Sullivan B, Su J, et al
    Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.
    Oral Oncol. 2022;125:105716.
    PubMed     Abstract available
    
    
    January 2022
28. WARD MC, Miller JA, Walker GV, Moeller BJ, et al
    The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: A simulation.
    Oral Oncol. 2022;126:105721.
    PubMed     Abstract available
    
    
    
29. CARDIN GB, Bernard M, Bourbonnais J, Bahig H, et al
    The rs6942067 genotype is associated with a worse overall survival in young or non-smoking HPV-negative patients with positive nodal status in head and neck squamous cell carcinoma.
    Oral Oncol. 2022;125:105696.
    PubMed    
    
    
    December 2021
30. WANG J, Tian Y, Huang H, Huang D, et al
    The prognosis of HPV-associated metastatic pharyngeal patients by primary and distant site.
    Oral Oncol. 2021;125:105675.
    PubMed     Abstract available
    
    
    
31. HERNDON P, Jassal JS, Cramer JD
    Association between E-cigarette use and oral HPV-16 infection.
    Oral Oncol. 2021;125:105676.
    PubMed    
    
    
    November 2021
32. KOWALCHUK RO, Van Abel KM, Yin LX, Garcia J, et al
    Correlation between radiographic and pathologic lymph node involvement and extranodal extension via CT and PET in HPV-associated oropharyngeal cancer.
    Oral Oncol. 2021;123:105625.
    PubMed     Abstract available
    
    
    
33. GOLUSINSKI P, Corry J, Poorten VV, Simo R, et al
    De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
    Oral Oncol. 2021;123:105620.
    PubMed     Abstract available
    
    
    
34. MCDOWELL L, Casswell G, Bressel M, Drosdowsky A, et al
    Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort.
    Oral Oncol. 2021;122:105560.
    PubMed     Abstract available
    
    
    October 2021
35. SHINN JR, Carey RM, Mady LJ, Shimunov D, et al
    Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;123:105570.
    PubMed     Abstract available
    
    
    
36. SHISHODIA G, Toledo RRG, Rong X, Zimmerman E, et al
    4NQO enhances differential activation of DNA repair proteins in HPV positive and HPV negative HNSCC cells.
    Oral Oncol. 2021;122:105578.
    PubMed     Abstract available
    
    
    
37. ROSENBERG AJ, Agrawal N, Pearson A, Gooi Z, et al
    Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
    Oral Oncol. 2021;122:105566.
    PubMed     Abstract available
    
    
    
38. HARING CT, Brummel C, Bhambhani C, Jewell B, et al
    Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation.
    Oral Oncol. 2021;121:105332.
    PubMed    
    
    
    September 2021
39. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2021;122:105503.
    PubMed     Abstract available
    
    
    August 2021
40. WRIGHT CM, Lee DY, Shimunov D, Carmona R, et al
    Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery.
    Oral Oncol. 2021;121:105509.
    PubMed     Abstract available
    
    
    
41. FIACCHINI G, Benettini G, Trico D, Torregrossa L, et al
    Human papillomavirus-related head and neck adenosquamous carcinoma: A systematic review and individual patient data meta-analysis.
    Oral Oncol. 2021;119:105252.
    PubMed     Abstract available
    
    
    July 2021
42. NAUTA IH, Klausch T, van de Ven PM, Hoebers FJP, et al
    The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis.
    Oral Oncol. 2021;121:105454.
    PubMed     Abstract available
    
    
    
43. KIM C, Martinez E, Kulich M, Swanson MS, et al
    Surgeon practice patterns in transoral robotic surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2021;121:105460.
    PubMed     Abstract available
    
    
    
44. MCDOWELL L, Gough K, King M, Corry J, et al
    Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer - A review of the literature and PRO methodology.
    Oral Oncol. 2021;118:105309.
    PubMed     Abstract available
    
    
    June 2021
45. PATEL KB, Mroz EA, Faquin WC, Rocco JW, et al
    A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy.
    Oral Oncol. 2021;120:105421.
    PubMed     Abstract available
    
    
    
46. DAHLSTROM KR, Anderson KS, Guo M, Kwon MC, et al
    Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial.
    Oral Oncol. 2021;120:105397.
    PubMed     Abstract available
    
    
    
47. BIDINOTTO AB, Kops NL, Bessel M, Maranhao AGK, et al
    Prevalence of oral HPV infection in unvaccinated young adults in Brazil.
    Oral Oncol. 2021;120:105396.
    PubMed     Abstract available
    
    
    
48. LENZE NR, Farquhar DR, Sheth S, Zevallos JP, et al
    Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma.
    Oral Oncol. 2021;119:105377.
    PubMed     Abstract available
    
    
    May 2021
49. COSTANTINO A, De Virgilio A, Spriano G
    Is the current oropharyngeal cancer T classification adequate in the era of HPV and transoral robotic surgery?
    Oral Oncol. 2021 May 25:105359. doi: 10.1016/j.oraloncology.2021.105359.
    PubMed    
    
    
    
50. ZHOU L
    Concerns about human papillomavirus-associated oropharyngeal cancer detection methods.
    Oral Oncol. 2021;116:105143.
    PubMed    
    
    
    April 2021
51. YVER CM, Shimunov D, Weinstein GS, Rajasekaran K, et al
    Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery.
    Oral Oncol. 2021;118:105307.
    PubMed     Abstract available
    
    
    
52. RAJASEKARAN K, Carey RM, Lin X, Seckar TD, et al
    The microbiome of HPV-positive tonsil squamous cell carcinoma and neck metastasis.
    Oral Oncol. 2021;117:105305.
    PubMed     Abstract available
    
    
    
53. KREINBRINK PJ, Li J, Parajuli S, Wise-Draper TM, et al
    Pre-treatment absolute lymphocyte count predicts for improved survival in human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2021;116:105245.
    PubMed     Abstract available
    
    
    
54. DHAKAL R, Moeller BJ, Prabhu RS, Frenkel CH, et al
    Pattern of distant metastasis in oropharyngeal carcinoma - Do they differ by HPV status?
    Oral Oncol. 2021 Apr 18:105286. doi: 10.1016/j.oraloncology.2021.105286.
    PubMed    
    
    
    March 2021
55. KIM HAJ, Zeng PYF, Shaikh MH, Mundi N, et al
    All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles.
    Oral Oncol. 2021;116:105260.
    PubMed     Abstract available
    
    
    February 2021
56. FREIHAT O, Toth Z, Pinter T, Kedves A, et al
    Pre-treatment PET/MRI based FDG and DWI imaging parameters for predicting HPV status and tumor response to chemoradiotherapy in primary oropharyngeal squamous cell carcinoma (OPSCC).
    Oral Oncol. 2021;116:105239.
    PubMed     Abstract available
    
    
    
57. FADEN DL, O'Boyle CJ, Lin DT, Deschler DG, et al
    Prospective assessment of multiple HPV-positive oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2021 Feb 15:105212. doi: 10.1016/j.oraloncology.2021.105212.
    PubMed    
    
    
    
58. CHATFIELD-REED K, Roche VP, Pan Q
    cfDNA detection for HPV+ squamous cell carcinomas.
    Oral Oncol. 2021;115:104958.
    PubMed     Abstract available
    
    
    
59. MENEZES FDS, Fernandes GA, Antunes JLF, Villa LL, et al
    Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: A systematic review of population-based studies.
    Oral Oncol. 2021;115:105177.
    PubMed     Abstract available
    
    
    January 2021
60. YILMAZ E, Ozbun MA, Gan GN
    Molecular and immune signature of HPV-positive oral cavity squamous cell carcinoma.
    Oral Oncol. 2021 Jan 25:105175. doi: 10.1016/j.oraloncology.2020.105175.
    PubMed    
    
    
    
61. PILAR A, Yu E, Su J, O'Sullivan B, et al
    Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma.
    Oral Oncol. 2021;114:105167.
    PubMed     Abstract available
    
    
    
62. BHATTASALI O, Torres FA, Kang HK, Thompson LDR, et al
    Prognostic impact of retropharyngeal lymphadenopathy in early-stage HPV-associated oropharyngeal cancer: Implications for staging optimization.
    Oral Oncol. 2021;114:105147.
    PubMed    
    
    
    December 2020
63. CHRISTOPHERSON KM, Moreno AC, Elgohari B, Gross N, et al
    Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation.
    Oral Oncol. 2020;113:105125.
    PubMed     Abstract available
    
    
    October 2020
64. FLEMING CW, Ward MC, Woody NM, Joshi NP, et al
    Identifying an oligometastatic phenotype in HPV-associated oropharyngeal squamous cell cancer: Implications for clinical trial design.
    Oral Oncol. 2020;112:105046.
    PubMed     Abstract available
    
    
    
65. MILLIET F, Bozec A, Schiappa R, Viotti J, et al
    Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study.
    Oral Oncol. 2020;112:105041.
    PubMed     Abstract available
    
    
    
66. CONTRERA KJ, Smile TD, Mahomva C, Wei W, et al
    Locoregional and distant recurrence for HPV-associated oropharyngeal cancer using AJCC 8 staging.
    Oral Oncol. 2020;111:105030.
    PubMed     Abstract available
    
    
    June 2020
67. IQBAL MS, Warner L, Paleri V, Kovarik J, et al
    De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era.
    Oral Oncol. 2020;105:104768.
    PubMed    
    
    
    April 2020
68. PATEL RR, Ludmir EB, Augustyn A, Zaorsky NG, et al
    De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
    Oral Oncol. 2020;103:104608.
    PubMed     Abstract available
    
    
    
69. CANAVAN JF, Harr BA, Bodmann JW, Reddy CA, et al
    Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer.
    Oral Oncol. 2020;103:104585.
    PubMed     Abstract available
    
    
    March 2020
70. SANDULACHE VC, Lei YL, Heasley LE, Chang M, et al
    Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.
    Oral Oncol. 2020;102:104440.
    PubMed    
    
    
    January 2020
71. CHATFIELD-REED K, Gui S, O'Neill WQ, Teknos TN, et al
    HPV33+ HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes.
    Oral Oncol. 2020;100:104488.
    PubMed     Abstract available
    
    
    
72. CHEN C, Lohavanichbutr P, Zhang Y, Houck JR, et al
    Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples.
    Oral Oncol. 2020;100:104487.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Sexually Transmitted Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: